Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X FTSE Southeast Asia ETF (ASEA) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance

Global X FTSE Southeast Asia ETFTrade
Citius Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Global X FTSE Southeast Asia ETF vs Citius Pharmaceuticals Inc — how do they compare? Global X FTSE Southeast Asia ETF trades at $21.43, while Citius Pharmaceuticals Inc trades at $0.76 (market cap $20.01M). The key difference: Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

ASEACTXR
Sector
Sector/ThematicHealth
52-Week High
$21.53$1.82
52-Week Low
$16.86$0.48
Market Cap
$20.01M
Enterprise Value
$16.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X FTSE Southeast Asia ETF

No Aura AI signal available yet.

Citius Pharmaceuticals Inc

CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.

The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X FTSE Southeast Asia ETF

ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.

Read more on ASEA

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR